Sales: $7.7 billion for skin, baby and oral care products.
Corporate sales: $65 billion.
Key Personnel: William C. Weldon, chairman; Alex Gorsky, chief executive officer; Dominic J. Caruso, VP-finance and chief financial officer; Peter M. Fasolo, VP-global human resources; Michael H. Ullmann, VP, general counsel.
Major Products: Baby Care—Johnson’s Baby; Skin Care— Aveeno, Clean & Clear, Johnson’s Adult, Neutrogena, RoC, Lubriderm, Dabao and Vendôme; Oral Care—Listerine and Reach.
New Products: Neosporin Essentials, Neutrogena All-in-One Acne Control, Wet Skin sunblock spray and Neutrogena Naturals face and lip products, Aveeno Smart Essentials, Listerine Zero.
Comments: Corporate sales rose 5.6% after two years of declines. Consumer sales rose 2% to $14.9 billion, but operating profit fell 10.5% to $2 billion, due primarily to the recall of several OTC products.
Taking a closer look within the consumer health care business, sales of skin care products jumped 7.6% in 2011 to $3.7 billion due to gains from Neutrogena, Dabao, Johnson’s Adult and Le Petit Marseillais.
Aveeno expanded its collection with this Intense Moisture variation.
Finally, oral care sales rose 6.4% to $1.6 billion thanks to higher sales of Listerine.
J&J said it spent $659 million on consumer product research last year.
For Q1 2012, corporate sales declined 0.2% to $16.1 billion, but the company noted that Neutrogena and some oral care products posted gains in the quarter. More specifically, global consumer healthcare sales fell 2.4% to nearly $3.6 billion in Q1. Skin care sales rose 0.9% to $907 million. Oral care sales declined 1% to $387 million and baby care sales fell 3.7% to $540 million.
The big personnel move, of course, was vice chairman Sheri S. McCoy’s April resignation to become CEO of Avon Products.